10X Genomics (TXG)
NASDAQ:TXG
Want to see TXG full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.24Last Year’s EPS
0.28Same Quarter Last Year
Moderate Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized a major product milestone (Atara) with strong consumables momentum, margin improvement, expense discipline, and a strengthened cash position, balanced against notable near-term headwinds in instrument revenue, limited initial Atara production capacity, and modest full-year growth guidance. Management framed the instrument declines as temporary and incorporated anticipated customer timing shifts into guidance, while positioning Atara and existing platforms to drive longer-term TAM expansion, AI-driven demand, and translational adoption.Company Guidance
Revenue Growth (Excluding Prior-Year Settlement)
Q1 revenue was $150.8M, up 9% year-over-year when excluding nonrecurring settlement revenue from the prior-year period.
Strong Consumables Performance
Total consumables revenue grew 13% year-over-year; single cell consumables were up 6% (driven by double-digit growth in reaction volumes from FLEX and FLEX Apex) and spatial consumables grew 31%, driven by Xenium momentum.
Gross Margin Improvement
Gross margin improved to 70% in Q1 2026 from 68% in the prior-year period, primarily driven by lower warranty costs and lower inventory write-downs.
Operating Expense Reductions and Improved Cash Position
Total operating expenses decreased 15% year-over-year (20% lower excluding the prior-year one-time settlement gain); company ended the quarter with $540M in cash, cash equivalents, and marketable securities—up $113M year-over-year and up $16M sequentially.
Atara Launch — Major Product Introduction
Launched Atara, described as the company's most significant product introduction: enables spatial whole-transcriptome analysis with single-cell sensitivity at scale, processes up to 800 whole-transcriptome 1cm2 samples per instrument per year (over 3,000 with targeted Atara Select panels), uses standard glass slides, on-board GPU image processing, and a long-term upgradable roadmap (automation, protein multiomics, in situ sequencing, 10x Cloud enhancements). Early customer response and preorders described as extraordinary.
Partnerships and AI Tailwind
Notable partnerships and initiatives (Chan Zuckerberg Initiative Building Cell Project, Arc Institute Virtual Cell Challenge, Zira Therapeutics perturbation dataset, Biooptimus ‘Stella’ initiative, Chan Zuckerberg Biohub $100M virtual biology initiative) reinforcing demand for large-scale, high-quality biological data and positioning 10x as key data generator for AI-driven biology.
Product Leadership and Translational Momentum
FLEX Apex cited as a game changer for large translational studies (FFPE compatibility, streamlined workflows, cost profile for large cohorts); Xenium driving spatial consumable growth and enabling translational and clinical cohort work.
Maintained Full-Year Outlook
Company maintained full-year 2026 revenue guidance of $600M to $625M, which (excluding 2025 settlement revenue) implies approximately 0% to 4% growth year-over-year and incorporates Atara launch dynamics.
TXG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TXG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $22.42 | $21.60 | -3.66% |
Feb 12, 2026 | $17.51 | $18.12 | +3.48% |
Nov 06, 2025 | $13.00 | $15.25 | +17.31% |
Aug 07, 2025 | $12.80 | $12.29 | -3.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does 10X Genomics (TXG) report earnings?
10X Genomics (TXG) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is 10X Genomics (TXG) earnings time?
10X Genomics (TXG) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TXG EPS forecast?
TXG EPS forecast for the fiscal quarter 2026 (Q2) is -0.24.